Abstract | BACKGROUND: PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. Maintenance therapy including pemetrexed and bevacizumab was given to patients with non-progressive disease. The primary evaluation criterion was safety. Secondary evaluation criteria were response rate, progression-free survival (PFS) and overall survival (OS). RESULTS: Thirty-eight patients (50% males, median age: 55 years, range 38-76) received a total of 199 cycles (median per patient: 6, range 2-6), plus 98 cycles of maintenance therapy. Twenty patients (52.6%) had a PS of 2, and 6 (15.8%) had brain metastases. The most frequent toxicities were hypertension (all grades: 42.1%) and peripheral neuropathy (grade 2-3: 21.1%). Haematological toxicities included grade 4 neutropenia, grade 3 anaemia and thrombopenia (5.3% each). Neither febrile neutropenia nor arterial thrombo-embolic event occurred. The objective response rate was 55.3% (95%CI: 39.5-71.1). The median PFS and OS were 6.2 (95%CI: 5.4-9.0) and 14.6 (95%CI: 9.8-19.5) months, respectively. CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC.
|
Authors | Olivier Mir, Pascaline Boudou-Rouquette, Julie Giroux, Jeanne Chapron, Jérôme Alexandre, Laure Gibault, Stanislas Ropert, Romain Coriat, Jean-Philippe Durand, Pierre-Régis Burgel, Daniel Dusser, François Goldwasser |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 77
Issue 1
Pg. 104-9
(Jul 2012)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 22364783
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Glutamates
- Organoplatinum Compounds
- Pemetrexed
- Oxaliplatin
- Bevacizumab
- Guanine
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology)
- Disease-Free Survival
- Female
- Glutamates
(administration & dosage)
- Guanine
(administration & dosage, analogs & derivatives)
- Humans
- Hypertension
(chemically induced)
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Maintenance Chemotherapy
- Male
- Middle Aged
- Neoplasm Staging
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Pemetrexed
- Retrospective Studies
- Treatment Outcome
|